Literature DB >> 19376307

New precompetitive paradigms: focus on cardiac safety.

John Finkle, Daniel Bloomfield, Kathleen Uhl, Wendy Sanhai, Norman Stockbridge, Mitchell W Krucoff.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19376307     DOI： 10.1016/j.ahj.2009.02.021

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  3 in total

Review 1.  [Polypharmacy is of major concern in cardiology].

Authors:  Peter Dovjak; Ulrike Sommeregger; Ronald Otto; Regina E Roller; Birgit Böhmdorfer; Bernhard Iglseder; Ursula Benvenuti-Falger; Monika Lechleitner; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

2.  Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.

Authors:  Tim Eisen; Yaroslav Shparyk; Nicholas Macleod; Robert Jones; Gudrun Wallenstein; Graham Temple; Yasser Khder; Claudia Dallinger; Matus Studeny; Arsene-Bienvenu Loembe; Igor Bondarenko
Journal:  Invest New Drugs       Date:  2013-04-27       Impact factor: 3.850

Review 3.  Assessing cardiac safety in oncology drug development.

Authors:  Jonathan H Seltzer; Gary Gintant; Laleh Amiri-Kordestani; Jack Singer; Luana Pesco Koplowitz; Javid J Moslehi; Ana Barac; Anthony F Yu
Journal:  Am Heart J       Date:  2019-05-04       Impact factor: 4.749
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.